CYBB and atherosclerosis: Users of ENDS show reduced endothelial function and increased serum markers of inflammation and oxidative stress, particularly NOX2 (a reduced isoform of nicotinamide adenine dinucleotide phosphate); this relates to the development of endothelial dysfunction and progression toward atherosclerosis [76].